Literature DB >> 8416159

Malignant polyps: are they sheep in wolves' clothing?

R L Koretz1.   

Abstract

One of the arguments supporting the concept that benign adenomatous polyps of the colon degenerate into cancer is the observation of malignancy in polypoid growths known to have been present for years. Although a latent phase--the duration of time between the initial development of a malignancy and the subsequent occurrence of a clinical problem--must exist, this argument implies that this time span is not many years. If both the prevalence of malignant polyps and the incidence of consequent symptomatic colon cancer were known, the average latent phase could be calculated. In order to estimate this prevalence, I used autopsy data; the estimate was validated using independent data fro three colonoscopic screening studies. The annual incidence of all colon cancer in the United States is approximately 150,000 cases. I estimate that 725,000 people in the United States harbor at least one malignant polyp. Even if all 150,000 cases of colon cancer were associated with symptoms and began as malignant polyps, the average latent phase is 4.8 years. Because some colon cancers are removed while the patient is still asymptomatic (discovered on screening examination) and because at least some colon cancers arise de novo from the mucosa, the average latent phase must be even longer. These estimates suggest that it cannot be assumed that the histologic finding of cancer in a polyp that has been observed for many years represents "malignant degeneration" of a previously benign neoplasm; such a malignancy may have had that histologic characteristic from the start. Further, histologically ominous lesions (malignant polyps) may often have prolonged benign clinical courses.

Entities:  

Mesh:

Year:  1993        PMID: 8416159     DOI: 10.7326/0003-4819-118-1-199301010-00011

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  13 in total

Review 1.  New trends in molecular and cellular biomarker discovery for colorectal cancer.

Authors:  Parisa Aghagolzadeh; Ramin Radpour
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

2.  Colorectal cancer deaths attributable to nonuse of screening in the United States.

Authors:  Reinier G S Meester; Chyke A Doubeni; Iris Lansdorp-Vogelaar; S Lucas Goede; Theodore R Levin; Virginia P Quinn; Marjolein van Ballegooijen; Douglas A Corley; Ann G Zauber
Journal:  Ann Epidemiol       Date:  2014-12-05       Impact factor: 3.797

3.  State disparities in colorectal cancer rates: Contributions of risk factors, screening, and survival differences.

Authors:  Iris Lansdorp-Vogelaar; S Lucas Goede; Jiemin Ma; Wu Xiau-Cheng; Karen Pawlish; Marjolein van Ballegooijen; Ahmedin Jemal
Journal:  Cancer       Date:  2015-07-06       Impact factor: 6.860

4.  Can the adenoma detection rate reliably identify low-performing endoscopists? Results of a modeling study.

Authors:  Sameer D Saini; Philip Schoenfeld; Sandeep Vijan
Journal:  Dig Dis Sci       Date:  2013-03-02       Impact factor: 3.199

5.  Colorectal adenoma and cancer divergence. Evidence of multilineage progression.

Authors:  J L Tsao; S Tavaré; R Salovaara; J R Jass; L A Aaltonen; D Shibata
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

6.  Telomerase activity is commonly detected in hereditary nonpolyposis colorectal cancers.

Authors:  Z H Li; R Salovaara; L A Aaltonen; D Shibata
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

7.  Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity.

Authors:  Djenaba A Joseph; Reinier G S Meester; Ann G Zauber; Diane L Manninen; Linda Winges; Fred B Dong; Brandy Peaker; Marjolein van Ballegooijen
Journal:  Cancer       Date:  2016-05-20       Impact factor: 6.860

8.  At what costs will screening with CT colonography be competitive? A cost-effectiveness approach.

Authors:  Iris Lansdorp-Vogelaar; Marjolein van Ballegooijen; Ann G Zauber; Rob Boer; Janneke Wilschut; J Dik F Habbema
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

9.  Tracing cell fates in human colorectal tumors from somatic microsatellite mutations: evidence of adenomas with stem cell architecture.

Authors:  J L Tsao; J Zhang; R Salovaara; Z H Li; H J Järvinen; J P Mecklin; L A Aaltonen; D Shibata
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

10.  Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies.

Authors:  Hermann Brenner; Michael Hoffmeister; Christa Stegmaier; Gerhard Brenner; Lutz Altenhofen; Ulrike Haug
Journal:  Gut       Date:  2007-06-25       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.